ATE404178T1 - Vorrichtung mit matrixgesteuerter wirkstofffreisetzung - Google Patents

Vorrichtung mit matrixgesteuerter wirkstofffreisetzung

Info

Publication number: ATE404178T1
Authority: AT; Austria
Prior art keywords: matrix; active release; controlled active; spray; dosage form
Prior art date: 1999-02-10

Application number

AT00300546T

Other languages

English (en)

Inventor

Leah Elizabeth Appel

Dwayne Thomas Friesen

William John Curatolo

James Alan Schrive Nightingale

Avinash Govind Thombre

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-10

Filing date

2000-01-26

Publication date

2008-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22384221&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE404178(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-01-26 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2008-08-15 Application granted granted Critical

2008-08-15 Publication of ATE404178T1 publication Critical patent/ATE404178T1/de

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
239000002552 dosage form Substances 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
229940079593 drug Drugs 0.000 abstract 2
239000011159 matrix material Substances 0.000 abstract 2
238000013270 controlled release Methods 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229920000642 polymer Polymers 0.000 abstract 1
239000007962 solid dispersion Substances 0.000 abstract 1
239000007921 spray Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Hematology (AREA)
Obesity (AREA)
Immunology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Oncology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Psychology (AREA)
Tropical Medicine & Parasitology (AREA)
Rheumatology (AREA)
Virology (AREA)
Nutrition Science (AREA)
Hospice & Palliative Care (AREA)

AT00300546T 1999-02-10 2000-01-26 Vorrichtung mit matrixgesteuerter wirkstofffreisetzung ATE404178T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US11940099P	1999-02-10	1999-02-10

Publications (1)

Publication Number	Publication Date
ATE404178T1 true ATE404178T1 (de)	2008-08-15

Family

ID=22384221

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00300546T ATE404178T1 (de)	1999-02-10	2000-01-26	Vorrichtung mit matrixgesteuerter wirkstofffreisetzung

Country Status (7)

Country	Link
EP (1)	EP1027887B1 (de)
JP (2)	JP4355779B2 (de)
AT (1)	ATE404178T1 (de)
BR (1)	BR0000359A (de)
CA (1)	CA2298245C (de)
DE (1)	DE60039802D1 (de)
ES (1)	ES2310164T3 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2000281561A (ja) *	1999-03-26	2000-10-10	Ajinomoto Co Inc	新規溶媒法固体分散体製剤
BR0016555A (pt) *	1999-12-23	2002-09-17	Pfizer Prod Inc	Composições farmacêuticas que proporcionam concentrações acrescidas de droga
AR028253A1 (es) *	2000-03-16	2003-04-30	Pfizer Prod Inc	Inhibidores de la glucogeno fosforilasa
DE10026698A1 (de)	2000-05-30	2001-12-06	Basf Ag	Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
KR20020014570A (ko) *	2000-08-18	2002-02-25	김충섭	고체분산화시킨 무정형 이프리플라본의 제조방법
GB0027357D0 (en) *	2000-11-09	2000-12-27	Bradford Particle Design Plc	Particle formation methods and their products
ES2333645T3 (es)	2001-06-22	2010-02-25	Bend Research, Inc.	Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros.
DE60220049T2 (de)	2001-06-22	2007-08-30	Pfizer Products Inc., Groton	Pharmazeutische Zusammensetzung, umfassend eine feste Dispersion eines im Wasser schwer löslichen Arzneimittels und ein löslichkeitssteigerndes Polymer
CZ20033456A3 (en)	2001-06-22	2004-07-14	Pfizer Products Inc.	Pharmaceutical compositions comprising adsorbates of amorphous drug
PL368587A1 (en)	2001-06-22	2005-04-04	Pfizer Products Inc.	Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers
EP1269994A3 (de)	2001-06-22	2003-02-12	Pfizer Products Inc.	Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
JP2004534811A (ja) *	2001-06-22	2004-11-18	ファイザー・プロダクツ・インク	ポリマーと薬剤の集合体を含む医薬組成物
US7105178B2 (en)	2001-07-17	2006-09-12	Sun Pharmaceutical Industries Limited	Cardiotonic composition
JP2005509001A (ja) *	2001-10-29	2005-04-07	セリクス，インコーポレイテッド	投薬形態の三次元懸濁液プリンティング
EP1474123A1 (de) *	2002-01-03	2004-11-10	LEK Pharmaceuticals D.D.	Venlafaxin enthaltende pharmazeutische formulierung mit kontrollierter freisetzung
JP2005522424A (ja) *	2002-02-01	2005-07-28	ファイザー・プロダクツ・インク	コレステリルエステル転移タンパク質インヒビターの制御放出性薬剤投与形態
MXPA04007433A (es)	2002-02-01	2004-10-11	Pfizer Prod Inc	Procedimiento para preparar dispersiones solidas amorfas homogeneas de farmaco secadas por pulverizacion utilizando un dispositivo de secado por pulverizacion modificado.
MXPA04007428A (es)	2002-02-01	2004-10-11	Pfizer Prod Inc	Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido.
JP2005523262A (ja)	2002-02-01	2005-08-04	ファイザー・プロダクツ・インク	薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
PL371593A1 (en)	2002-02-01	2005-06-27	Pfizer Products Inc.	Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
EP1505987A2 (de) *	2002-05-13	2005-02-16	Pharmacia Corporation	Stabile amorphe celecoxib komposite und verfahren deren
SI21223A (sl) *	2002-06-19	2003-12-31	Krka, Tovarna Zdravil, D.D., Novo Mesto	Farmacevtska formulacija s stabiliziranim amorfnim donepezilijevim kloridom
AU2003249474A1 (en)	2002-08-12	2004-02-25	Pfizer Products Inc.	Pharmaceutical compositions of semi-ordered drugs and polymers
US7423004B2 (en)	2003-01-31	2008-09-09	Smithkline Beecham Corporation	Solid dispersion compositions
IL154370A0 (en) *	2003-02-10	2003-09-17	Chemagis Ltd	Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
DE10325989A1 (de) *	2003-06-07	2005-01-05	Glatt Gmbh	Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
CL2004001884A1 (es)	2003-08-04	2005-06-03	Pfizer Prod Inc	Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
ATE540671T1 (de)	2003-08-04	2012-01-15	Bend Res Inc	Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien
MXPA06001506A (es) *	2003-08-04	2006-05-15	Pfizer Prod Inc	Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductasa.
US8377952B2 (en)	2003-08-28	2013-02-19	Abbott Laboratories	Solid pharmaceutical dosage formulation
US8025899B2 (en)	2003-08-28	2011-09-27	Abbott Laboratories	Solid pharmaceutical dosage form
AR048431A1 (es) *	2004-03-17	2006-04-26	Novartis Ag	Formulaciones galenicas de compuestos organicos
JP2008511609A (ja) *	2004-08-31	2008-04-17	ファイザー・プロダクツ・インク	低−溶解性薬物の速放及び徐放を組み合わせた制御放出型投薬形態
KR20070046892A (ko)	2004-08-31	2007-05-03	화이자 프로덕츠 인크.	저용해도 약물 및 중합체를 포함하는 제약 투여형
CA2581926A1 (en)	2004-09-29	2006-04-06	Chemagis Ltd.	Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride
AU2005320547B2 (en)	2004-12-27	2009-02-05	Eisai R & D Management Co., Ltd.	Method for stabilizing anti-dementia drug
US20090208579A1 (en) *	2004-12-27	2009-08-20	Eisai R & D Management Co., Ltd.	Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US9265731B2 (en)	2005-01-28	2016-02-23	Bend Research, Inc.	Drying of drug-containing particles
WO2006082500A1 (en) *	2005-02-03	2006-08-10	Pfizer Products Inc.	Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
JP5026426B2 (ja) *	2005-08-29	2012-09-12	サノフイ−アベンテイス・ユー・エス・エルエルシー	７−クロロ−Ｎ，Ｎ，５−トリメチル−４−オキソ−３−フェニル−３，５−ジヒドロ−４Ｈ−ピリダジノ［４，５−ｂ］インドール−１−アセトアミドのアモルファス固体分散体
EP2043610B1 (de)	2006-07-21	2015-07-01	Bend Research, Inc.	Trocknung von arzneimittelhaltigen teilchen
PE20081506A1 (es)	2006-12-12	2008-12-09	Infinity Discovery Inc	Formulaciones de ansamicina
JP2010523589A (ja) *	2007-04-03	2010-07-15	ドクターレディズラボラトリーズリミテッド	ペメトレキセドの固体形
EP2155166A2 (de) *	2007-05-11	2010-02-24	F. Hoffmann-Roche AG	Pharmazeutische zusammensetzung für schwer lösliche heilmittel
JP5048398B2 (ja) *	2007-06-13	2012-10-17	大蔵製薬株式会社	抗真菌剤の医薬組成物
SMT202000093T1 (it) *	2009-06-16	2020-03-13	Pfizer	Forme di dosaggio di apixaban
US8329208B2 (en) *	2009-07-28	2012-12-11	Methylation Sciences International Srl	Pharmacokinetics of S-adenosylmethionine formulations
ES2414384T3 (es) *	2011-05-11	2013-07-19	Ratiopharm Gmbh	Composición de liberación modificada que comprende ranolazina
JO3339B1 (ar) *	2012-09-11	2019-03-13	Shanghai Inst Pharmaceutical Ind	شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
WO2014059522A1 (en)	2012-10-17	2014-04-24	Methylation Sciences International Srl	Compositions comprising s-adenosylmethionine and a gallic acid ester
JP5836980B2 (ja)	2013-01-11	2015-12-24	信越化学工業株式会社	薬物含有粒子、固形製剤及び薬物含有粒子の製造方法
JP6505705B2 (ja) *	2013-12-05	2019-04-24	アルライズバイオシステムズゲゼルシャフトミットベシュレンクテルハフツング	経口投与用製剤の製造方法
MX2016014574A (es) *	2014-05-08	2017-02-23	Oncoethix Gmbh	El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo.
CA2987867C (en)	2015-06-09	2023-06-27	Capsugel Belgium Nv	Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
GB201609222D0 (en)	2016-05-25	2016-07-06	F2G Ltd	Pharmaceutical formulation
US11819503B2 (en)	2019-04-23	2023-11-21	F2G Ltd	Method of treating coccidioides infection
CN113840595A (zh) *	2019-05-17	2021-12-24	葛兰素史密斯克莱知识产权发展有限公司	基质组合物，其包含(S)-5-苄基-N-(5-甲基-4-氧代-2,3,4,5-四氢苯并[b][1,4]氧氮杂环庚三烯-3-基)-4H-1,2,4-三唑-3-甲酰胺
CN119424434A (zh) *	2019-09-18	2025-02-14	百时美施贵宝公司	Tyk2抑制剂的剂型
KR20260020944A (ko)	2023-05-15	2026-02-12	보나파이드 헬스, 엘엘씨	수면 개선 조성물 및 이용 방법
WO2025062372A1 (en)	2023-09-21	2025-03-27	Takeda Pharmaceutical Company Limited	Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
WO2026033474A1 (en)	2024-08-08	2026-02-12	Takeda Pharmaceutical Company Limited	Deuterated compounds and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5948810B2 (ja) *	1980-03-22	1984-11-29	山之内製薬株式会社	ニカルジピン持続性製剤用組成物
JPS5649314A (en) *	1979-07-05	1981-05-02	Yamanouchi Pharmaceut Co Ltd	Lasting pharmaceutical composition having prolonged action and its preparation
JPS58116414A (ja) *	1981-12-23	1983-07-11	Yamanouchi Pharmaceut Co Ltd	ニカルジピン持続性製剤用球形顆粒およびその製造法
JP2528706B2 (ja) *	1988-05-30	1996-08-28	ゼリア新薬工業株式会社	ジヒドロピリジン化合物の製剤組成物
TW212139B (de) *	1991-04-15	1993-09-01	Yamanouchi Pharma Co Ltd
IT1250654B (it) *	1991-07-08	1995-04-21	Farcon Ag	Metodo per la preparazione di forme farmaceutiche orali a rilascio prolungato contenenti sostanze attive a solubilita' dipendente dal valore di ph.
JP2516524B2 (ja) *	1992-04-27	1996-07-24	大洋薬品工業株式会社	持続性製剤
US5773025A (en) *	1993-09-09	1998-06-30	Edward Mendell Co., Inc.	Sustained release heterodisperse hydrogel systems--amorphous drugs
NZ283160A (en) *	1994-05-06	1998-07-28	Pfizer	Azithromycin in a controlled release dosage form for treating microbiol infections
DE19515972A1 (de) *	1995-05-02	1996-11-07	Bayer Ag	Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung
IE80467B1 (en) *	1995-07-03	1998-07-29	Elan Corp Plc	Controlled release formulations for poorly soluble drugs
TW487582B (en) *	1995-08-11	2002-05-21	Nissan Chemical Ind Ltd	Method for converting sparingly water-soluble medical substance to amorphous state
DE69837903T2 (de) *	1997-08-11	2008-02-14	Pfizer Products Inc., Groton	Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit

2000
- 2000-01-26 AT AT00300546T patent/ATE404178T1/de not_active IP Right Cessation
- 2000-01-26 EP EP00300546A patent/EP1027887B1/de not_active Expired - Lifetime
- 2000-01-26 ES ES00300546T patent/ES2310164T3/es not_active Expired - Lifetime
- 2000-01-26 DE DE60039802T patent/DE60039802D1/de not_active Expired - Lifetime
- 2000-02-09 CA CA002298245A patent/CA2298245C/en not_active Expired - Lifetime
- 2000-02-10 BR BR0000359-0A patent/BR0000359A/pt not_active Application Discontinuation
- 2000-02-10 JP JP2000033446A patent/JP4355779B2/ja not_active Expired - Fee Related
2005
- 2005-08-04 JP JP2005226695A patent/JP4694298B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ES2310164T3 (es)	2009-01-01
CA2298245A1 (en)	2000-08-10
JP2005320354A (ja)	2005-11-17
EP1027887A3 (de)	2001-02-28
EP1027887B1 (de)	2008-08-13
BR0000359A (pt)	2001-08-14
DE60039802D1 (de)	2008-09-25
JP4694298B2 (ja)	2011-06-08
JP4355779B2 (ja)	2009-11-04
CA2298245C (en)	2004-11-30
JP2000229888A (ja)	2000-08-22
EP1027887A2 (de)	2000-08-16

Legal Events

Date	Code	Title	Description
2009-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE404178T1 (de)	2008-08-15	Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
ATE227120T1 (de)	2002-11-15	Vorrichtungen zur intravaginalen verabreichung von testosteron und testosteron- vorläuferverbindungen
CY1109489T1 (el)	2014-08-13	Συσκευη χορηγησης φαρμακου
ES2144478T3 (es)	2000-06-16	Metodo y aparato para prevenir la opacificacion capsular posterior.
ATE433318T1 (de)	2009-06-15	Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
ES2120543T3 (es)	1998-11-01	Dispositivo para la aplicacion de injertos.
DE69635734D1 (de)	2006-04-06	Verbesserte formulierung zur gesteuerten arzneistofffreisetzung durch kombination hydrophiler und hydrophober stoffe
DK1125577T3 (da)	2006-06-19	Væskeformige medikamentindföringspræparater
WO2001030323A3 (en)	2002-02-21	Controlled-release biocompatible ocular drug delivery implant devices and methods
PT863729E (pt)	2005-04-29	Dispositivo implantavel de libertacao controlada para distribuir farmacos directamente a uma porcao interna do corpo
BR9609663A (pt)	1999-05-18	Formulações para desprendimento controlado de medicamentos fracamente soluveis
ITMI922603A1 (it)	1994-05-13	Composizioni farmaceutiche comprendenti un farmaco, una sostanza polimerica reticolata, un olio ed un agente tensioattivo
DK0654256T3 (da)	2000-12-18	Bionedbrydelig senehindetampon
AU5673399A (en)	2000-03-14	Compositions and methods for treating intracellular infections
EP0873751A3 (de)	1998-12-23	Pharmazeutisches produkt zur anwendung auf der mukosa der gebärmutter
DE69831940D1 (de)	2006-03-02	Tablette mit verlängerter Wirkstoffabgabe im Magen
FR2757064B1 (fr)	2000-02-04	Lentille intraoculaire contenant un medicament relargable
ES2178631T3 (es)	2003-01-01	Composicion a base de un oligomero y un polimero, inyectable y biodegradable.
DE60001717D1 (de)	2003-04-24	Mikrokapseln mit verzögerter freisetzung von wirkstoffen
CA2544460A1 (en)	2001-05-03	Controlled-release biocompatible ocular drug delivery implant devices and methods
HU9203420D0 (en)	1993-01-28	Biologically decomposable polymers for medical preparatives of delayed releqse of active agents
AR028670A1 (es)	2003-05-21	IMPLANTE DE TOXINA BOTULíNICA